Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with...
Saved in:
Published in | Journal of the American Heart Association Vol. 13; no. 7; p. e033720 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley and Sons Inc
02.04.2024
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with AF.
BMP10 was measured using a prototype Elecsys immunoassay in plasma samples collected at randomization and after 2 months in patients with AF randomized to apixaban or warfarin in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (n=2878). Adjusted Cox-regression models were used to evaluate the association between 2-month BMP10 levels and outcomes. BMP10 levels increased by 7.8% (
<0.001) over 2 months. The baseline variables most strongly associated with BMP10 levels at 2 months were baseline BMP10 levels, body mass index, sex, age, creatinine, diabetes, warfarin treatment, and AF-rhythm. During median 1.8 years follow-up, 34 ischemic strokes/systemic embolism, 155 deaths, and 99 heart failure hospitalizations occurred. Comparing the third with the first sample quartile, higher BMP10 levels at 2 months were associated with higher risk of ischemic stroke (hazard ratio [HR], 1.33 [95% CI, 0.67-2.63],
=0.037), heart failure (HR, 1.91 [95% CI, 1.17-3.12],
=0.012) and all-cause death (HR, 1.61 [95% CI, 1.17-2.21],
<0.001). Adding BMP10 levels at 2 months on top of established risk factors and baseline BMP10 levels improved the C-indices for ischemic stroke/systemic embolism (from 0.73 to 0.75), heart failure hospitalization (0.76-0.77), and all-cause mortality (0.70-0.72), all
<0.05.
Elevated levels of BMP10 at 2 months strengthened the associations with the risk of ischemic stroke, hospitalization for heart failure, and all-cause mortality. Repeated measurements of BMP10 may further refine risk stratification in patients with AF. |
---|---|
AbstractList | BACKGROUND: BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with AF. METHODS AND RESULTS: BMP10 was measured using a prototype Elecsys immunoassay in plasma samples collected at randomization and after 2 months in patients with AF randomized to apixaban or warfarin in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (n=2878). Adjusted Cox-regression models were used to evaluate the association between 2-month BMP10 levels and outcomes. BMP10 levels increased by 7.8% (P<0.001) over 2 months. The baseline variables most strongly associated with BMP10 levels at 2 months were baseline BMP10 levels, body mass index, sex, age, creatinine, diabetes, warfarin treatment, and AF-rhythm. During median 1.8 years follow-up, 34 ischemic strokes/systemic embolism, 155 deaths, and 99 heart failure hospitalizations occurred. Comparing the third with the first sample quartile, higher BMP10 levels at 2 months were associated with higher risk of ischemic stroke (hazard ratio [HR], 1.33 [95% CI, 0.67-2.63], P=0.037), heart failure (HR, 1.91 [95% CI, 1.17-3.12], P=0.012) and all-cause death (HR, 1.61 [95% CI, 1.17-2.21], P<0.001). Adding BMP10 levels at 2 months on top of established risk factors and baseline BMP10 levels improved the C-indices for ischemic stroke/systemic embolism (from 0.73 to 0.75), heart failure hospitalization (0.76-0.77), and all-cause mortality (0.70-0.72), all P<0.05. CONCLUSIONS: Elevated levels of BMP10 at 2 months strengthened the associations with the risk of ischemic stroke, hospitalization for heart failure, and all-cause mortality. Repeated measurements of BMP10 may further refine risk stratification in patients with AF. BACKGROUNDBMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with AF.METHODS AND RESULTSBMP10 was measured using a prototype Elecsys immunoassay in plasma samples collected at randomization and after 2 months in patients with AF randomized to apixaban or warfarin in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (n=2878). Adjusted Cox-regression models were used to evaluate the association between 2-month BMP10 levels and outcomes. BMP10 levels increased by 7.8% (P<0.001) over 2 months. The baseline variables most strongly associated with BMP10 levels at 2 months were baseline BMP10 levels, body mass index, sex, age, creatinine, diabetes, warfarin treatment, and AF-rhythm. During median 1.8 years follow-up, 34 ischemic strokes/systemic embolism, 155 deaths, and 99 heart failure hospitalizations occurred. Comparing the third with the first sample quartile, higher BMP10 levels at 2 months were associated with higher risk of ischemic stroke (hazard ratio [HR], 1.33 [95% CI, 0.67-2.63], P=0.037), heart failure (HR, 1.91 [95% CI, 1.17-3.12], P=0.012) and all-cause death (HR, 1.61 [95% CI, 1.17-2.21], P<0.001). Adding BMP10 levels at 2 months on top of established risk factors and baseline BMP10 levels improved the C-indices for ischemic stroke/systemic embolism (from 0.73 to 0.75), heart failure hospitalization (0.76-0.77), and all-cause mortality (0.70-0.72), all P<0.05.CONCLUSIONSElevated levels of BMP10 at 2 months strengthened the associations with the risk of ischemic stroke, hospitalization for heart failure, and all-cause mortality. Repeated measurements of BMP10 may further refine risk stratification in patients with AF. BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with AF. BMP10 was measured using a prototype Elecsys immunoassay in plasma samples collected at randomization and after 2 months in patients with AF randomized to apixaban or warfarin in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (n=2878). Adjusted Cox-regression models were used to evaluate the association between 2-month BMP10 levels and outcomes. BMP10 levels increased by 7.8% ( <0.001) over 2 months. The baseline variables most strongly associated with BMP10 levels at 2 months were baseline BMP10 levels, body mass index, sex, age, creatinine, diabetes, warfarin treatment, and AF-rhythm. During median 1.8 years follow-up, 34 ischemic strokes/systemic embolism, 155 deaths, and 99 heart failure hospitalizations occurred. Comparing the third with the first sample quartile, higher BMP10 levels at 2 months were associated with higher risk of ischemic stroke (hazard ratio [HR], 1.33 [95% CI, 0.67-2.63], =0.037), heart failure (HR, 1.91 [95% CI, 1.17-3.12], =0.012) and all-cause death (HR, 1.61 [95% CI, 1.17-2.21], <0.001). Adding BMP10 levels at 2 months on top of established risk factors and baseline BMP10 levels improved the C-indices for ischemic stroke/systemic embolism (from 0.73 to 0.75), heart failure hospitalization (0.76-0.77), and all-cause mortality (0.70-0.72), all <0.05. Elevated levels of BMP10 at 2 months strengthened the associations with the risk of ischemic stroke, hospitalization for heart failure, and all-cause mortality. Repeated measurements of BMP10 may further refine risk stratification in patients with AF. Background BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with AF. Methods and Results BMP10 was measured using a prototype Elecsys immunoassay in plasma samples collected at randomization and after 2 months in patients with AF randomized to apixaban or warfarin in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (n=2878). Adjusted Cox‐regression models were used to evaluate the association between 2‐month BMP10 levels and outcomes. BMP10 levels increased by 7.8% ( P <0.001) over 2 months. The baseline variables most strongly associated with BMP10 levels at 2 months were baseline BMP10 levels, body mass index, sex, age, creatinine, diabetes, warfarin treatment, and AF‐rhythm. During median 1.8 years follow‐up, 34 ischemic strokes/systemic embolism, 155 deaths, and 99 heart failure hospitalizations occurred. Comparing the third with the first sample quartile, higher BMP10 levels at 2 months were associated with higher risk of ischemic stroke (hazard ratio [HR], 1.33 [95% CI, 0.67–2.63], P =0.037), heart failure (HR, 1.91 [95% CI, 1.17–3.12], P =0.012) and all‐cause death (HR, 1.61 [95% CI, 1.17–2.21], P <0.001). Adding BMP10 levels at 2 months on top of established risk factors and baseline BMP10 levels improved the C‐indices for ischemic stroke/systemic embolism (from 0.73 to 0.75), heart failure hospitalization (0.76–0.77), and all‐cause mortality (0.70–0.72), all P <0.05. Conclusions Elevated levels of BMP10 at 2 months strengthened the associations with the risk of ischemic stroke, hospitalization for heart failure, and all‐cause mortality. Repeated measurements of BMP10 may further refine risk stratification in patients with AF. Background BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with AF. Methods and Results BMP10 was measured using a prototype Elecsys immunoassay in plasma samples collected at randomization and after 2 months in patients with AF randomized to apixaban or warfarin in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (n=2878). Adjusted Cox‐regression models were used to evaluate the association between 2‐month BMP10 levels and outcomes. BMP10 levels increased by 7.8% (P<0.001) over 2 months. The baseline variables most strongly associated with BMP10 levels at 2 months were baseline BMP10 levels, body mass index, sex, age, creatinine, diabetes, warfarin treatment, and AF‐rhythm. During median 1.8 years follow‐up, 34 ischemic strokes/systemic embolism, 155 deaths, and 99 heart failure hospitalizations occurred. Comparing the third with the first sample quartile, higher BMP10 levels at 2 months were associated with higher risk of ischemic stroke (hazard ratio [HR], 1.33 [95% CI, 0.67–2.63], P=0.037), heart failure (HR, 1.91 [95% CI, 1.17–3.12], P=0.012) and all‐cause death (HR, 1.61 [95% CI, 1.17–2.21], P<0.001). Adding BMP10 levels at 2 months on top of established risk factors and baseline BMP10 levels improved the C‐indices for ischemic stroke/systemic embolism (from 0.73 to 0.75), heart failure hospitalization (0.76–0.77), and all‐cause mortality (0.70–0.72), all P<0.05. Conclusions Elevated levels of BMP10 at 2 months strengthened the associations with the risk of ischemic stroke, hospitalization for heart failure, and all‐cause mortality. Repeated measurements of BMP10 may further refine risk stratification in patients with AF. |
Author | Gkarmiris, Konstantinos I Kastner, Peter Wallentin, Lars Ziegler, André Lindbäck, Johan Oldgren, Jonas Siegbahn, Agneta Hijazi, Ziad Alexander, John H Granger, Christopher B Lopes, Renato D |
AuthorAffiliation | 4 Roche Diagnostics GmbH Penzberg Germany 2 Uppsala Clinical Research Center, Uppsala University Uppsala Sweden 1 Department of Medical Sciences Cardiology, Uppsala University Uppsala Sweden 5 Department of Medical Sciences Clinical Chemistry, Uppsala University Uppsala Sweden 3 Duke Clinical Research Institute, Duke University School of Medicine Durham NC USA |
AuthorAffiliation_xml | – name: 2 Uppsala Clinical Research Center, Uppsala University Uppsala Sweden – name: 5 Department of Medical Sciences Clinical Chemistry, Uppsala University Uppsala Sweden – name: 3 Duke Clinical Research Institute, Duke University School of Medicine Durham NC USA – name: 4 Roche Diagnostics GmbH Penzberg Germany – name: 1 Department of Medical Sciences Cardiology, Uppsala University Uppsala Sweden |
Author_xml | – sequence: 1 givenname: Konstantinos I orcidid: 0009-0008-1453-0797 surname: Gkarmiris fullname: Gkarmiris, Konstantinos I organization: Uppsala Clinical Research Center, Uppsala University Uppsala Sweden – sequence: 2 givenname: Johan orcidid: 0000-0002-6473-8798 surname: Lindbäck fullname: Lindbäck, Johan organization: Uppsala Clinical Research Center, Uppsala University Uppsala Sweden – sequence: 3 givenname: John H orcidid: 0000-0002-1444-2462 surname: Alexander fullname: Alexander, John H organization: Duke Clinical Research Institute, Duke University School of Medicine Durham NC USA – sequence: 4 givenname: Christopher B orcidid: 0000-0002-0045-3291 surname: Granger fullname: Granger, Christopher B organization: Duke Clinical Research Institute, Duke University School of Medicine Durham NC USA – sequence: 5 givenname: Peter surname: Kastner fullname: Kastner, Peter organization: Roche Diagnostics GmbH Penzberg Germany – sequence: 6 givenname: Renato D orcidid: 0000-0003-2999-4961 surname: Lopes fullname: Lopes, Renato D organization: Duke Clinical Research Institute, Duke University School of Medicine Durham NC USA – sequence: 7 givenname: André surname: Ziegler fullname: Ziegler, André organization: Roche Diagnostics GmbH Penzberg Germany – sequence: 8 givenname: Jonas orcidid: 0000-0002-9969-3921 surname: Oldgren fullname: Oldgren, Jonas organization: Uppsala Clinical Research Center, Uppsala University Uppsala Sweden – sequence: 9 givenname: Agneta orcidid: 0000-0003-3955-5671 surname: Siegbahn fullname: Siegbahn, Agneta organization: Department of Medical Sciences Clinical Chemistry, Uppsala University Uppsala Sweden – sequence: 10 givenname: Lars orcidid: 0000-0003-0378-6531 surname: Wallentin fullname: Wallentin, Lars organization: Uppsala Clinical Research Center, Uppsala University Uppsala Sweden – sequence: 11 givenname: Ziad orcidid: 0000-0002-7420-743X surname: Hijazi fullname: Hijazi, Ziad organization: Uppsala Clinical Research Center, Uppsala University Uppsala Sweden |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38529655$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-528070$$DView record from Swedish Publication Index |
BookMark | eNpVkk1vEzEQhleoiJbQMzfkY5FIaq-9X1yqTWloUEKjNMDR8nrHidvddbB3i_iN_CmcTVs1PtjW-Jl3xqP3bXDUmAaC4D3BI0Jicv4tv85HJKQjTGkS4lfBSYhZMsyyFB-9uB8Hp87dYb_iMKFR9iY4pmkUZnEUnQT_lrAF0UKJ5iBcZ6GGpkVGoXYD6Lt5gArlrdWiQmNtamHvwaLxfEEwOhv7btDc2O3GrKGBVku0sKYF3SCCP6IlKN2AQ0vt7tFta0WrlZZ-Nw3ySN74BCPWXdVXX_gHX9mhX7rdPJWc6MLqqupzPqNp4_R645GJNXXfX76c3q5uVrMrtNrx74LXSlQOTh_PQfBjcrW6vB7Obr5OL_PZULKItENZYIUZY1QWJSlCSSQGRglOKEkLSNIUq1IKRosMh2HEhOegSAoV-jiNREkHwXSvWxpxx7dW-7n85UZo3geMXXNh_e8q4Coq0zJKChlTyjIpCkUZZrQUYcKUwsprfdpruT-w7YoDtS_6Z96rdR2PwhQn2OMXe9yzNZTSj8yK6iDr8KXRG742D5wQkmRJr3D2qGDN7w5cy2vtJPgpN2A6xymmhNA49uMYBOd7VFrjnAX1XIdgvnMg3zmQewfyvQN9xoeX7T3zT36j_wECJdt0 |
Cites_doi | 10.1136/heartjnl-2013-304872 10.1016/s0002-9149(02)03373-8 10.1093/eurheartj/ehac632 10.1056/NEJMoa1107039 10.1016/j.jacc.2012.11.082 10.1111/jth.14947 10.1111/bcpt.12834 10.1161/01.cir.98.10.946 10.1136/heartjnl-2018-313351 10.1016/j.jacc.2015.03.577 10.1093/europace/euw295 10.1161/CIRCULATIONAHA.111.038729 10.1016/S0140-6736(12)60986-6 10.1161/JAHA.122.028255 10.1074/jbc.M117.778506 10.3389/fcvm.2022.938567 10.1161/01.str.22.8.983 |
ContentType | Journal Article |
Copyright | 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. |
Copyright_xml | – notice: 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC DOA |
DOI | 10.1161/JAHA.123.033720 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Uppsala universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Uppsala universitet SwePub Articles full text DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Value of Repeated BMP10 Measurement in AF |
EISSN | 2047-9980 |
EndPage | e033720 |
ExternalDocumentID | oai_doaj_org_article_f5d8d57bc63349cabf34043da274ff0f oai_DiVA_org_uu_528070 10_1161_JAHA_123_033720 38529655 |
Genre | Randomized Controlled Trial Journal Article |
GroupedDBID | 0R~ 1OC 24P 53G 5VS 8-1 AAZKR ACGFO ACXQS ADBBV ADKYN ADZMN AEGXH AENEX AIAGR ALAGY ALMA_UNASSIGNED_HOLDINGS AOIJS AVUZU BAWUL BCNDV CGR CUY CVF DIK ECM EIF EMOBN GODZA GROUPED_DOAJ GX1 HYE KQ8 M48 M~E NPM OK1 RAH RHF RNS RPM WIN AAYXX CITATION 7X8 5PM ACNBI ADRAZ ADTPV AOWAS D8T DF2 EBS EJD H13 ZZAVC |
ID | FETCH-LOGICAL-c451t-cb0f04443cbd1b2c1c0e43107318be7880fdca43b902254a3cbeb7bf20fd35ad3 |
IEDL.DBID | RPM |
ISSN | 2047-9980 |
IngestDate | Thu Sep 05 15:35:42 EDT 2024 Fri Jul 05 03:15:08 EDT 2024 Tue Jun 25 20:30:55 EDT 2024 Wed Jul 17 03:54:34 EDT 2024 Fri Aug 23 01:16:24 EDT 2024 Wed Oct 02 05:19:30 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | BMP10 atrial fibrillation risk stratification biomarker stroke |
Language | English |
License | This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c451t-cb0f04443cbd1b2c1c0e43107318be7880fdca43b902254a3cbeb7bf20fd35ad3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 This article was sent to Luciano A. Sposato, MD, MBA, FRCPC, Associate Editor, for review by expert referees, editorial decision, and final disposition. For Sources of Funding and Disclosures, see page 9. |
ORCID | 0000-0002-0045-3291 0009-0008-1453-0797 0000-0002-1444-2462 0000-0003-2999-4961 0000-0002-7420-743X 0000-0003-3955-5671 0000-0002-9969-3921 0000-0002-6473-8798 0000-0003-0378-6531 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179770/ |
PMID | 38529655 |
PQID | 3031136607 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_f5d8d57bc63349cabf34043da274ff0f swepub_primary_oai_DiVA_org_uu_528070 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11179770 proquest_miscellaneous_3031136607 crossref_primary_10_1161_JAHA_123_033720 pubmed_primary_38529655 |
PublicationCentury | 2000 |
PublicationDate | 2024-04-02 |
PublicationDateYYYYMMDD | 2024-04-02 |
PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-02 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Hoboken |
PublicationTitle | Journal of the American Heart Association |
PublicationTitleAlternate | J Am Heart Assoc |
PublicationYear | 2024 |
Publisher | John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley and Sons Inc – name: Wiley |
References | e_1_3_1_8_2 e_1_3_1_13_2 e_1_3_1_7_2 e_1_3_1_12_2 e_1_3_1_11_2 e_1_3_1_9_2 e_1_3_1_10_2 e_1_3_1_4_2 e_1_3_1_17_2 e_1_3_1_3_2 e_1_3_1_16_2 e_1_3_1_6_2 e_1_3_1_15_2 e_1_3_1_5_2 e_1_3_1_14_2 e_1_3_1_2_2 e_1_3_1_18_2 |
References_xml | – ident: e_1_3_1_12_2 doi: 10.1136/heartjnl-2013-304872 – ident: e_1_3_1_4_2 doi: 10.1016/s0002-9149(02)03373-8 – ident: e_1_3_1_7_2 doi: 10.1093/eurheartj/ehac632 – ident: e_1_3_1_8_2 doi: 10.1056/NEJMoa1107039 – ident: e_1_3_1_11_2 doi: 10.1016/j.jacc.2012.11.082 – ident: e_1_3_1_15_2 doi: 10.1111/jth.14947 – ident: e_1_3_1_18_2 doi: 10.1111/bcpt.12834 – ident: e_1_3_1_5_2 doi: 10.1161/01.cir.98.10.946 – ident: e_1_3_1_10_2 doi: 10.1136/heartjnl-2018-313351 – ident: e_1_3_1_16_2 doi: 10.1016/j.jacc.2015.03.577 – ident: e_1_3_1_3_2 doi: 10.1093/europace/euw295 – ident: e_1_3_1_6_2 doi: 10.1161/CIRCULATIONAHA.111.038729 – ident: e_1_3_1_9_2 doi: 10.1016/S0140-6736(12)60986-6 – ident: e_1_3_1_13_2 doi: 10.1161/JAHA.122.028255 – ident: e_1_3_1_14_2 doi: 10.1074/jbc.M117.778506 – ident: e_1_3_1_17_2 doi: 10.3389/fcvm.2022.938567 – ident: e_1_3_1_2_2 doi: 10.1161/01.str.22.8.983 |
SSID | ssj0000627359 |
Score | 2.3779323 |
Snippet | BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial... Background BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with... BACKGROUNDBMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with... BACKGROUND: BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients... Background BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with... |
SourceID | doaj swepub pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | e033720 |
SubjectTerms | Anticoagulants - adverse effects Anticoagulants - therapeutic use atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy biomarker Biomarkers BMP10 Bone Morphogenetic Proteins - blood Bone Morphogenetic Proteins - chemistry Embolism Heart Failure - complications Heart Failure - drug therapy Humans Ischemic Stroke Original Research Risk Assessment - methods risk stratification stroke Stroke - epidemiology Stroke - etiology Stroke - prevention & control Warfarin - adverse effects Warfarin - therapeutic use |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4s2Wh4wEUjmExnGcONyy0NW2ImW1bKG3KH6pETRBm13-JH-KGSdbGoHEhatjyxPPePzZHn9DyEvGnDHOwUzjNgxiLXUgWWoCU2kpYpO6zOF75-I0mZ_FJ-fi_FqqL4wJ6-mB-4E7dMJII1KlE87jTFfKcSSEMRVsp5wLnfe-TFzbTPU-GJZlkQ1cPoBqDk_yOR788Tchx8Qso2XIs_X_DWL-GSk54hP1a9DsDrk9gEea90LfJTdsc4_cLIbr8fvkJ8Bp8K3W0OL30R9tHQWUR0_bHxba-jQddFq3lxiYs6bTYsFCejBtG0uLFka9BZPCl410gRQOdUNZ-JourcP4eLqsu6_UM9piiJHXKoUqeQMN2sqntYfeFz1Za0e_1JuLXZczfFzwrQ-9e0uPmw6PBTo6W7eXXr58efxp9XH14YiusP4DcjY7Wr2bB0O2hkDHgm0CrUKH5HNcK8NUpJkOLaATcCFMKgs77dAZXcVcZQAbRFxBPatS5SIo56Iy_CHZa-BfHxMqBHeJM9JWsY6tdEomGnSYWWZ1LE00IQc75ZXfe1KO0m9mElainkvQc9nreUKmqNyrasim7QvAxsrBxsp_2diEvNiZRgmzD69Uqsa2264EAIBJcZIwnZBHvalcdcUl3mkLMSFyZEQjWcZfmvrCM3wzJOpLU5D-VW9vozbv68-5l3-7LQWyGYX7_-Mvn5BbESA2H5YUPSV7m_XWPgPEtVHP_eT6Be4hLis priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELZgkRAXxJvykpFAWg5Z7NhO3ANCLbCqVsqqWlHYWxS_2IglgT4Q_CN-JjNOuquIHrimdu32m7G_icffEPKC8-BcCOBpwrNEWm0TzXOXuMpqJV0exgHvOxfH2Wwhj07V6WU5oP4PXO0M7bCe1GJ5fvDrx--34PBvosNn_PXRZIbv9MQBE1hz5Sq5lkoh0dyLnut3yzLs1LF4WorqBBBmsF7qZ8d3DHapKOa_i4H-m0g5kBuNW9ThLXKz55Z00hnDbXLFN3fI9aI_Pb9L_gDbhqXXO1pcvhmkbaBAAulx-9ND31jFg07r9hvm7SzptJhzRvenbeNp0QIoLVgcXnykc1R4qBvK2St64gOmz9OTevWVRsFbzECKoFNoMmmgQ1vFqvcw-rzTcl3Rz_X6bDvkId49OO8y8-6RxeGHj-9mSV-pIbFS8XViDQsoPCescdykllvmgZnA8sG18RBls-BsJYUZA2VQsoJ23uQmpPBcqMqJ-2SvgR_ykFClRMiC076SVnodjM4sADT23FupXToi-1tkyu-dIEcZA5mMlwhiCSCWHYgjMkXkLpqhknZ80C6_lL1jlkE57VRubCaEHNvKBIGCQ66CcD0EFkbk-Rb3EjwPj1OqxrebVQmbPxbEyVg-Ig86O7gYSmg8z1ZqRPTAQgZzGX7S1GdR3ZujSF-ew-xfdsY06PO-_jSJ899sSoVKRuzRf7Z7TG6kQMhi1lH6hOytlxv_FAjV2jyLjvIX4nkhhA priority: 102 providerName: Scholars Portal |
Title | Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38529655 https://www.proquest.com/docview/3031136607/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC11179770 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-528070 https://doaj.org/article/f5d8d57bc63349cabf34043da274ff0f |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa2PUx7QdwJl8lIII2HtHZtJy5v7VjVTWRUpYO9RfFti1iTqRf-JH-KY6cZq-CJlzwktuz2fLY_2-d8B6F3lDpjnIORxiyJuZY6ljQ1sSm0FNykru98vHN2nowv-NmluNxBSRsLE5z2tSo71c28U5XXwbfydq67rZ9Yd5IdU69jlqaku4t2U8bu7dGb-ReWZNHf6PgAo-meDcb-0I91CPNJWQ7QPpP-vtHH991bjYJo_7-Y5t8Ok1uyomEpGj1EDzYcEg-avj5CO7Z6jPazzS35E_QLWDVMsdbg7M8JIK4dBrKHz-ufFuqGbB14WNZz75-zwMNsQgk-GtaVxVkNf34NyPIBjnjilRzKClPyAU-t827yeFouf-AgbOs9jYJxMRQZVFChLkJ2e2h90mi2LvH3cnXdNjnyMQY3jQfeR3xaLf3pwBKPFvU89G8wPf06-zL7fIJnvvxTdDE6mR2P403ShlhzQVexVsR5DTqmlaGqp6kmFkgKzCRUKgsbbuKMLjhTfWAPghdQzqpUuR68Z6Iw7Bnaq-C3vkBYCOYSZ6QtuOZWOiUTDebsW2o1l6YXoaPWePlto82Rhz1NQnNv8hxMnjcmj9DQG_eumBfVDi_qxVW-gVbuhJFGpEonjPG-LpRjXnvIFLBzd464CL1toZHDIPQ3K0Vl6_UyBx7gc-MkJI3Q8wYqd021UIuQ3ALRVl-2vwDug9B3i_MIvW_wtlXnU_ltEPq_XufCixqRl__fxCt00AO6FnySeq_R3mqxtm-Abq3UYTimgGfG5WEYab8B1rowBg |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JbxMxGLVKkUov7EtYjQRSOUwyHs8WbklplJRMiEK63EbjrR21mamycOAv8qf4Pk-mNMAFrjO2bMvP9rP9_D5C3jFmlDIGRhrXruPLWDoxi5SjMhkHvopM2-B752QU9o_8w9PgdIuE9VsYK9qXIm8Wl7NmkZ9bbeXVTLZqnVhrnOwz9DGLIrd1i9yGAetFN3bp1QwMi3LQXjv5AKdpHXb6eOzHmy7HsCy7ZIfHeOOIL_xurEfWtv9vXPNPyeSGsahdjHr3yEndjEqDctFcLUVTfv_N4fHf23mf3F3zU9qp_j8gW7p4SHaS9Q38I_IDGDtM31rR5NfpIi0NBSJJR-U3DXltJBDazcsZan_mtJuMmUv3umWhaVJCx5aAWnw8ScfoEpEXlLkf6EQblODTSb64oNY0F1VMFjgUknQKyFBmZxhuDEofV36wC3qSL8_rInv4fuGyUvd9pINigScPC9qblzNbv85k8HX6ZTo8oFNM_5gc9Q6m-31nHRDCkX7Alo4UrkF_Oy6FYsKTTLoaCBDMUiwWGjbzrlEy87loAzMJ_AzSaREJ48F3HmSKPyHbBbT1GaFBwE1oVKwzX_o6NiIOJQClrZmWfqy8BtmrYZFeVb4fqd0vhSxFMKUAprQCU4N0ETbXydCw234o52fpujtTE6hYBZGQIed-W2bCcPQ1UpkX-ca4pkHe1qBLYYDjrU1W6HK1SIFjYNyd0I0a5GkFwuuiahA3SLwBz426bP4BrFkT8RpbDfK-QvJGnk_5ccfWf7VKAzRMcp__fxFvyJ3-NBmmw8Ho8wuy6wEttNon7yXZXs5X-hXQuqV4bcfwT50_UGE |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLVgSNVeuF_C1UggjYe0cZwrb-22qh1LqUoHk3iI4tsWbU2qpuWBv8if4rOTjBV42mtiy7Z8bB_bx-dD6B0hSgilYKRR6dgej7gdkVDYIuOR74lQxUq_d04mwejEOzr1TxtVZdXIKgvO8m5xuegW-bnRVi4XvNfqxHrTZJ9oH7MwdHpLoXq30R0YtG58badez8KwMPtx4-YDvKZ31B_poz_adagOzbKLOjTSt476ld-1NclY9_-Pb_4rm9wyFzUL0vAe-t42pdahXHQ3a9blP_9yebxZW--juw1Pxf06zQN0SxYPUSdpbuIfoV_A3GEalwInf04ZcakwEEo8KX9IyGsiguBBXi60BmiFB8mUOHhvUBYSJyV0cAno1Y8o8VS7ReQFJs4HPJNKS_HxLK8usDHP1WomAyAMSfoFZCizMx12DEqf1r6wFf6Wr8_bIof6HcNlrfL7iMdFpU8gKjxclQtTv_5s_GX-eX58iOc6_WN0Mjyc74_sJjCEzT2frG3OHKV97ihngjCXE-5IIEIwW5GISdjUO0rwzKMsBobiexmkkyxkyoXv1M8EfYJ2CmjrM4R9n6pAiUhmHvdkpFgUcABLLInkXiRcC-210EiXtf9HavZNAUk1oFIAVFoDykIDDZ2rZNq423woV2dp06Wp8kUk_JDxgFIv5hlTVPsbicwNPaUcZaG3LfBSGOj69iYrZLmpUuAaOv5O4IQWeloD8aqoFsgWirYgulWX7T-AN2Mm3uLLQu9rNG_lOci_9k39N5vU18ZJzvObF_EGdaYHw_R4PPn0Au26wA6NBMp9iXbWq418BexuzV6bYfwb8F1S4Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Repeated+Measurement+of+the+Novel+Atrial+Biomarker+BMP10+%28Bone+Morphogenetic+Protein+10%29+Refines+Risk+Stratification+in+Anticoagulated+Patients+With+Atrial+Fibrillation&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Gkarmiris%2C+Konstantinos+I.&rft.au=Lindb%C3%A4ck%2C+Johan&rft.au=Alexander%2C+John+H.&rft.au=Granger%2C+Christopher+B.&rft.date=2024-04-02&rft.issn=2047-9980&rft.eissn=2047-9980&rft.volume=13&rft.issue=7&rft_id=info:doi/10.1161%2FJAHA.123.033720&rft.externalDocID=oai_DiVA_org_uu_528070 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon |